Gastrointestinal pH and Transit Time Profiling in Healthy Volunteers Using the IntelliCap System Confirms Ileo-Colonic Release of ColoPulse Tablets

Abstract

IntroductionColoPulse tablets are an innovative development in the field of oral dosage forms characterized by a distal ileum and colon-specific release. Previous studies in humans showed release in the ileo-colonic region, but the relationship between gastrointestinal pH and release was not experimentally proven in vivo. This information will complete the in vivo release-profile of ColoPulse tablets.Materials and MethodsRelease from ColoPulse tablets was studied in 16 healthy volunteers using the dual label isotope strategy. To determine gastrointestinal pH profiles and transit times the IntelliCap system was used. A ColoPulse tablet containing 13C-urea and an uncoated, immediate release tablet containing 15N2-urea were taken simultaneously followed by a standardized breakfast after three hours. Five minutes after intake of the tablets the IntelliCap capsule was swallowed and pH was measured until excretion in the feces. Breath and urine samples were collected for isotope analysis.ResultsFull analysis could be performed in 12 subjects. Median bioavailability of 13C -urea was 82% (95% CI 74–94%, range 61–114%). The median lag time (5% release of 13C) was 5:42 h (95% CI 5:18–6:18 h, range 2:36–6:36 h,) There was no statistically significant difference between lag time based on isotope signal and colon arrival time (CAT) based on pH (median 5:42 vs 5:31 h p = 0.903). In all subjects an intestinal pH value of 7.0 was reached before release of 13C from the ColoPulse tablet occurred.Discussion and ConclusionsFrom the combined data from the IntelliCap system and the 13C -isotope signal it can be concluded that release from a ColoPulse tablet in vivo is not related to transit times but occurs in the ileo-colonic region after pH 7.0 is reached. This supports our earlier findings and confirms that the ColoPulse system is a promising delivery system for targeting the distal ileum and colon.Trial RegistrationISRCTN Registry 18301880

A pH Switch for β‐Sheet Protein Folding

“…For instance, the difference in pH from the lower stomach to the small intestine is from ~2.5 to ~7 respectively. [28] If a classic [4:6] turn is not tolerated at the position of mutation, it was found that adding two or four glycines on either side ( G2_pHSW and G4_pHSW ) provides 10 – 14 residue loops that still function as a pH switch, these could be used as loop and β-turn replacements in other β-sheets. Our pH dependent conformational switch is small, uses natural amino acids and operates under mild conditions.…”

FcRn binding is not sufficient for achieving systemic therapeutic levels of immunoglobulin G after oral delivery of enteric‐coated capsules in cynomolgus macaques

“…Intestinal pH profiling and dosing was performed by IntelliCap System ® capsules (~size 000 containing ~184 μ L), which are approved for clinical use for profiling (Maurer et al. ) and drug delivery (Becker et al. ) by operator‐controlled computer monitoring.…”

“…Intestinal pH in cynomolgus has not been previously reported. Intestinal pH profiling and dosing was performed by IntelliCap System â capsules (~size 000 con-taining~184 lL), which are approved for clinical use for profiling (Maurer et al 2015) and drug delivery (Becker et al 2014) by operator-controlled computer monitoring. Nine monkeys (six fasted o/n and three fed) were given empty IntelliCap System â capsules (~size 000) by oral dosing for profiling gastrointestinal pH.…”

Randomised clinical study: inulin short‐chain fatty acid esters for targeted delivery of short‐chain fatty acids to the human colon

“…Targeting small molecule delivery to the large intestine is challenging because the vector has to avoid absorption in the small intestine, resist digestion by brush-border and exocrine enzymes and thereafter selectively release its small molecule payload in the large intestine. Techniques for small molecule colonic delivery such as encapsulation, using fermentable polymer coatings, 23 pH and/ or time-dependant release 24 and direct instillation, using SCFA enema 25 are limited to relatively low dosing regimens or are unsuitable for population-level interventions. The binding affinity between FFAR and SCFA appears adapted for the relatively high SCFA concentrations found in colonic environment, resulting to a key specification of any colonic delivery system for SCFA: it must be capable of inducing significant change in the large colonic SCFA pool.…”